```html

Latent Tuberculosis Infection (LTBI) – A Complete Patient Guide

Overview

Latent tuberculosis infection (LTBI) occurs when Mycobacterium tuberculosis bacteria have entered the body and are alive, but the immune system has contained them so that no active disease develops.

• What it is: A non‑contagious state in which the bacteria are dormant. People with LTBI feel healthy, have no symptoms, and cannot spread TB to others.
​
• Who it affects: Anyone can be infected, but the likelihood is higher in people with frequent exposure to TB (e.g., healthcare workers, close contacts of an active case, people born in high‑prevalence regions).
• Prevalence: According to the World Health Organization (WHO), about 1.7 billion people worldwide (~ 23 % of the global population) are estimated to have LTBI. In the United States, the CDC estimates roughly 8 million people (≈ 2.5 % of the population) have LTBI.

While most people with LTBI never develop active tuberculosis (TB), a small proportion (5‑10 % over a lifetime) will progress to active disease, especially if the immune system weakens.

Symptoms

By definition, LTBI does not cause symptoms. However, it is important to differentiate it from active TB, which does have a characteristic symptom profile. If any of the following appear, the infection may have progressed to active disease and requires urgent medical evaluation.

Symptoms of Active TB (for comparison)

• Persistent cough lasting >3 weeks, sometimes with blood‑tinged sputum.
• Fever—often low‑grade and worse in the evenings.
• Night sweats that soak clothing or bedding.
• Unexplained weight loss or loss of appetite.
• Fatigue and general feeling of weakness.
• Chest pain or shortness of breath (especially if lung involvement is extensive).
• Other organ‑specific signs (e.g., lymph node enlargement, meningitis, joint pain) when TB spreads outside the lungs.

Causes and Risk Factors

How LTBI develops

TB is transmitted through airborne droplets when a person with active pulmonary TB coughs, sneezes, or speaks. Inhaled bacilli reach the alveoli, where they may:

1. Be destroyed by macrophages (most people).
2. Survive inside macrophages, leading to a *primary* infection.
3. Result in a dormant state (LTBI) when the immune response walls off the bacteria in granulomas.

Only a minority of infected individuals progress to active disease without treatment.

Risk factors for acquiring LTBI

• Living or traveling in regions with high TB prevalence (e.g., sub‑Saharan Africa, South‑East Asia, Eastern Europe).
• Close contact with a person who has active pulmonary TB.
• Working in health‑care, correctional facilities, or congregate housing (shelters, nursing homes).
• Immunocompromising conditions: HIV infection, diabetes, chronic kidney disease, silicosis, malignancy, or use of TNF‑α inhibitors.
• Age extremes: young children and older adults have weaker immune responses.
• Malnutrition, smoking, and excessive alcohol use, which impair host defenses.

Diagnosis

Since LTBI produces no symptoms, diagnosis relies on tests that detect the immune response to TB antigens.

1. Tuberculin Skin Test (TST)

• Procedure: 0.1 mL of purified protein derivative (PPD) is injected intradermally on the forearm. The induration (raised, hardened area) is measured 48–72 hours later.
• Interpretation: Cut‑off varies by risk group:
  • ≥5 mm for HIV‑positive, recent contacts, or immunosuppressed patients.
  • ≥10 mm for recent immigrants, injection‑drug users, or diabetics.
  • ≥15 mm for low‑risk individuals.
• Limitations: False‑positives in BCG‑vaccinated people, cross‑reactivity with non‑tuberculous mycobacteria, requires a return visit.

2. Interferon‑Gamma Release Assays (IGRAs)

• Two FDA‑approved IGRAs: QuantiFERON‑TB Gold Plus and T‑Spot.TB.
• How they work: Patient’s blood is mixed with TB‑specific antigens (ESAT‑6, CFP‑10). If T‑cells have been sensitized, they release interferon‑γ, which is measured.
• Advantages: Single visit, not affected by BCG vaccination, high specificity.
• Limitations: Higher cost, requires laboratory infrastructure, may be indeterminate in severely immunocompromised patients.

3. Additional Evaluations

Once LTBI is identified, clinicians must rule out active TB:

• Chest radiograph (CXR): Looks for infiltrates, cavitation, or healed lesions.
• Sputum smear & culture: Performed only if CXR or symptoms suggest active disease.
• Medical history & physical exam: To assess risk of progression.

Treatment Options

Treatment aims to eradicate dormant bacilli and prevent future active disease. Several regimens are recommended by the CDC, WHO, and American Thoracic Society, chosen based on drug tolerability, patient comorbidities, and likelihood of adherence.

First‑line Regimens

Regimen	Drugs & Dose	Duration	Key Points
Isoniazid (INH) monotherapy	INH 300 mg daily (adults) + vitamin B6 25 mg	6–9 months	Most studied; risk of hepatotoxicity; requires monthly liver function monitoring.
Rifampin (RIF) monotherapy	RIF 600 mg daily	4 months	Lower hepatotoxicity; interacts with many meds (e.g., oral contraceptives, anticoagulants).
Isoniazid + Rifapentine (3HP)	INH 900 mg + Rifapentine 900 mg once weekly	12 weeks (once weekly)	Convenient; high completion rates; safe in many groups, but not in pregnancy.
Isoniazid + Rifampin (4HR)	INH 300 mg + RIF 600 mg daily	4 months	Shorter than INH alone; same drug‑interaction cautions as rifampin.

Special Populations

• Children < 5 years: 6‑month INH is preferred; 3HP can be used if weight‑based dosing is achievable.
• Pregnant women: INH + pyridoxine for ≥9 months is recommended; avoid rifampin/ rifapentine unless benefits outweigh risks.
• HIV‑positive: 3HP or 4HR are preferred for better adherence; monitor for drug interactions with antiretrovirals.
• Renal/hepatic impairment: Dose adjustments for INH; avoid rifampin if severe hepatic disease.

Monitoring & Side‑Effect Management

• Baseline liver function tests (ALT/AST) and repeat every 1‑2 months for regimens containing INH or rifampin.
• Educate patients about symptoms of hepatotoxicity (e.g., nausea, dark urine, jaundice) and instruct them to stop medication and seek care immediately.
• Vitamin B6 (pyridoxine) is given with INH to prevent peripheral neuropathy.
• Adherence support: directly observed therapy (DOT), phone reminders, or combination with fixed‑dose tablets.

Living with Latent Tuberculosis Infection

Having LTBI does not restrict normal activities, but following a few practical steps helps ensure successful treatment and protects overall health.

• Take medication exactly as prescribed. Use a pillbox or set daily alarms.
• Track side effects. Keep a simple diary of any new symptoms.
• Maintain routine medical follow‑up. Attend all scheduled lab tests and clinic visits.
• Stay hydrated and maintain a balanced diet. Good nutrition supports liver health.
• Avoid alcohol excess. Alcohol can increase the risk of drug‑induced liver injury.
• Inform other healthcare providers. Let dentists, surgeons, and specialists know you are on TB medication, as some drugs interact with rifampin.
• Vaccinations. Keep up‑to‑date with flu and COVID‑19 vaccines; they do not interfere with LTBI treatment.

Prevention

Preventing LTBI (and subsequent active TB) involves public‑health and personal measures.

• Screen high‑risk groups: recent immigrants, healthcare workers, close contacts of active TB cases, and people with HIV.
• BCG vaccine: Widely used in high‑incidence countries; it protects mainly against severe pediatric TB, not adult LTBI.
• Infection control in healthcare settings: Use negative‑pressure isolation rooms and respirators (N95) for patients with suspected/confirmed active TB.
• Reduce exposure: Improve ventilation in crowded living conditions and encourage cough etiquette.
• Manage comorbidities: Good glycemic control in diabetes, smoking cessation, and treatment of HIV reduce progression risk.

Complications

If LTBI is left untreated, the main complication is progression to active TB, which can be severe:

• Pulmonary destruction: Cavities, fibrosis, and chronic respiratory impairment.
• Disseminated (miliary) TB: Widespread organ involvement, especially in immunocompromised patients.
• TB meningitis or spinal TB (Pott disease): High mortality and lasting neurological deficits.
• Drug‑resistant TB: Incomplete treatment of active disease can select for multidrug‑resistant (MDR) strains, which are much harder to cure.

Early treatment of LTBI dramatically reduces these risks—by >90 % according to CDC data.

When to Seek Emergency Care

---

Sources: Centers for Disease Control and Prevention (CDC). Guidelines for Treatment of Latent Tuberculosis Infection, 2023. World Health Organization. Global Tuberculosis Report 2024. Mayo Clinic. Latent TB infection. National Institute of Allergy and Infectious Diseases. TB Treatment. Cleveland Clinic. TB – Diagnosis and Treatment.

```